Skip to content
value.today

NeoGenomics, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Diagnostics and Research: $1.7 B to $5.9 B, median $3.9 BPrice to bookPrice to book of Diagnostics and Research: $2.6 B to $11.8 B, median $5.8 B$0 M$3.2 B$6.4 B$9.5 B$12.7 BMarket value $2.2 B

Your own DCF model

A full discounted-cash-flow model of NeoGenomics, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Diagnostics and Research

Multiples of its companies with a market value at most 60 days old, times NeoGenomics, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)NeoGenomics, Inc.Applied toValue (25th to 75th)Companies
Price to sales2.3× / 5.4× / 8.1×2.8×revenue $727 M$1.7 B to $5.9 B36
Price to book3.1× / 6.9× / 14.1×2.6×book equity $837 M$2.6 B to $11.8 B34

Against its own history

NeoGenomics, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to sales

2.9×

Now above its median of 2.3×; range 1.0× to 14.6× over 30 months.

0×4×7×11×15×2020202120222023202420252026Price to sales 3×Median 2×

Price to book

2.6×

Now above its median of 1.8×, in the top quarter of its range; range 0.7× to 11.8× over 30 months.

0×3×6×9×12×2020202120222023202420252026Price to book 3×Median 2×

As of Oct 15, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$727 M$-108 M$5 M$27 M$-22 M$182 MSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$661 M$-79 M$7 M$41 M$-34 M$174 MSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$592 M$-88 M$-2 M$29 M$-31 M$196 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$510 M$-144 M$-66 M$31 M$-97 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$484 M$-8 M$-27 M$64 M$-91 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$444 M$4 M$1 M$29 M$-28 M—SEC annual report (10-K, 20-F)